argenx NV ADR (ARGX)vsJazz Pharmaceuticals PLC (JAZZ)
ARGX
argenx NV ADR
$984.39
+0.04%
HEALTHCARE · Cap: $64.63B
JAZZ
Jazz Pharmaceuticals PLC
$245.80
+2.21%
HEALTHCARE · Cap: $15.58B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 16% more annual revenue ($5.32B vs $4.60B). ARGX leads profitability with a 32.3% profit margin vs 20.4%. JAZZ appears more attractively valued with a PEG of 0.96. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
JAZZ
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$2371.09
Current Price
$984.39
$1386.70 discount
Margin of Safety
+51.8%
Fair Value
$344.71
Current Price
$245.80
$98.91 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Keeps 20 of every $100 in revenue as profit
Growing faster than its price suggests
Attractively priced relative to earnings
Strong operational efficiency at 26.9%
15.5% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 183.0x book value
3.2% earnings growth
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : JAZZ
The strongest argument for JAZZ centers on Profit Margin, PEG Ratio, P/E Ratio. Profitability is solid with margins at 20.4% and operating margin at 26.9%. Revenue growth of 15.5% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : JAZZ
The primary concerns for JAZZ are EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
JAZZ carries more volatility with a beta of 0.36 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 72/100), backed by strong 32.3% margins and 59.3% revenue growth. JAZZ offers better value entry with a 51.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Jazz Pharmaceuticals PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?